MedTrace Logo

Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers

NCT04611061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 204

Last updated 2020-11-02

No results posted yet for this study

Summary

this study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in morbidity in Russia in the 2017-2018 season (epidemiology: number of cases during the period of taking Kagocel and follow-up, severity of the disease, bacterial exacerbations, number of repeated episodes (reinfection); patients demography; safety) in health care workers who are at risk.

Conditions

  • Acute Upper Respiratory Tract Infection
  • Influenza
  • Respiratory Viral Infection

Interventions

DRUG

Kagocel

Investigators could prescribe other drugs in frame of routine clinical practice

DRUG

No one

Investigators don't prescribe any antiviral drugs in frame of routine clinical practice

Sponsors & Collaborators

  • Nearmedic Plus LLC

    lead INDUSTRY

Principal Investigators

  • Vladimir Petrov, Dr. habilitated, Professor · Department of infectious diseases of Obninsk institute for nuclear power engineering (OINPE)

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-02
Primary Completion
2017-12-13
Completion
2018-06-14

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04611061 on ClinicalTrials.gov